Shopping Cart 0
Cart Subtotal
AED 0

KOL Perspectives: Selective JAK inhibitors in IBD

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 27525

Details

KOL Perspectives: Selective JAK inhibitors in IBD

Summary

This KOL Insight briefing focuses on KOLs views of selective JAK inhibitors in IBD.

The briefing includes analysis of KOL opinion on the following topic areas-

- Maintenance data for selective JAKs in Crohn's disease

- Differentiating strategies for selective and non-selective JAKs in IBD

- Choice of primary endpoints for IBD trials?Selective JAKs' expected efficacy in UC

- Real-world use of JAKs in IBD

Key Highlights

- KOLs were broadly impressed with upadacitinib's Week 52 data in Crohn's disease, but views of filgotinib's Week 20 data were mixed

- Most KOLs stated that upadacitinib maintenance data matched and reinforced positive expectations for upadacitinib in Crohn's disease

- KOL consensus is that mid-range doses (6/12mg), or extended release equivalents should be used in upadacitinib's Phase III program.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based

- Interviews performed during June 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "selective JAK inhibitors in IBD"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Tofacitinib, upadacitinib, filgotinib, ozanimod, apremilast


Companies

Pfizer

AbbVie

Gilead

Galapagos

Celgene

Company Profile

Company Profile Title

KOL Perspectives: Selective JAK inhibitors in IBD

Summary

This KOL Insight briefing focuses on KOLs views of selective JAK inhibitors in IBD.

The briefing includes analysis of KOL opinion on the following topic areas-

- Maintenance data for selective JAKs in Crohn's disease

- Differentiating strategies for selective and non-selective JAKs in IBD

- Choice of primary endpoints for IBD trials?Selective JAKs' expected efficacy in UC

- Real-world use of JAKs in IBD

Key Highlights

- KOLs were broadly impressed with upadacitinib's Week 52 data in Crohn's disease, but views of filgotinib's Week 20 data were mixed

- Most KOLs stated that upadacitinib maintenance data matched and reinforced positive expectations for upadacitinib in Crohn's disease

- KOL consensus is that mid-range doses (6/12mg), or extended release equivalents should be used in upadacitinib's Phase III program.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based

- Interviews performed during June 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "selective JAK inhibitors in IBD"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Tofacitinib, upadacitinib, filgotinib, ozanimod, apremilast


Companies

Pfizer

AbbVie

Gilead

Galapagos

Celgene